|
Gemcitabine & oxaliplatin Clinical Trials
3 actively recruiting trials across 1 location
Also known as: GEMOX
Pipeline
Phase 2: 3
Top Sponsors
- The First Affiliated Hospital with Nanjing Medical University1
- National Research Center for Hematology, Russia1
- Massachusetts General Hospital1
Indications
- Cancer3
- Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)1
- Relapsed or Refractory B-cell Lymphoma1
- Relapsed/Refractory Large B-cell Lymphoma1
- B-cell Lymphomas1
Other2 trials
Phase 2
Boston, Massachusetts1 trial
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
Massachusetts General Hospital
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.